Top Medical News
LNG-IUD may have systemic effects
Roshini Claire Anthony, 31 minutes ago

A small study presented at RSNA 2021 has suggested that the use of levonorgestrel-releasing intrauterine contraceptive devices (LNG-IUDs) may affect background parenchymal enhancement (BPE).

Carbocisteine, gingko leaf extract boost milrinone’s efficacy against COPD complicated by PAH
31 minutes ago
The combination of carbocisteine, gingko leaf extract, and milrinone yields significant clinical improvement in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), a recent study has found. In turn, this treatment regimen also leads to better patient quality of life.
Postmenopausal women with low BMD: Exercise or bisphosphonates?
Pearl Toh, 4 hours ago
Postmenopausal women with low bone mass are encouraged to participate in bone-loading exercises and maintain adequate intake of calcium and vitamin D (CaD), while the addition of risedronate along with CaD can significantly improve BMD, particularly at the spine — such are the key messages of a recent study.
Loss of smell highly prevalent in mild COVID-19 cases than severe ones
Jairia Dela Cruz, 4 hours ago
A quick, objective testing kit for daily self-assessment of olfactory and gustatory function can effectively measure smell and taste losses associated with COVID-19, as shown in a study.
Endoscopic safer than radiological gastrostomy tube placement
5 hours ago
Percutaneous endoscopic gastrostomy (PEG) leads to fewer adverse outcomes and lower 30-day mortality than interventional radiologist-guided gastrostomy (IRG), according to a study.
Older age, insulin use, stroke linked to diabetic peripheral neuropathy in T2DM
Stephen Padilla, 6 hours ago
Diabetic peripheral neuropathy (DPN) is not uncommon among patients with type 2 diabetes mellitus (T2DM) in Singapore and is significantly associated with increased age, Indian ethnicity, insulin use, diabetic retinopathy, and stroke, according to a recent study.
Is ART safe for women with ulcerative colitis, Crohn's Disease?
7 hours ago
Assisted reproductive technology (ART) is both safe and effective in women with ulcerative colitis and medically managed Crohn’s disease (CD), with comparable pregnancy and live birth rates to those of the general population, a study has shown.
Special Reports
The Role of NOAC in Pandemic Era (TREND)
07 Dec 2021
At a Pfizer-sponsored Masterclass, four distinguished speakers shared their insights into the role of NOACs in the management of NVAF and VTE, with a focus on apixaban (Eliquis®, Pfizer). Furthermore, the speakers discussed a stepwise approach to guide treatment choice amid the COVID-19 pandemic.
Product Highlight - Locoa
01 Dec 2021
Esflurbiprofen 40 mg transdermal patch
Product Highlight - Rinvoq
01 Dec 2021
Upadacitinib 15 mg XR-FC tab
01 Dec 2021
It has been estimated that diabetes – a chronic metabolic disorder resulting in hyperglycaemia – affects 422 million adults globally.1 In 2019, the disease caused 1.5 million deaths worldwide and the number of people with diabetes is expected to reach 642 million by 2040. 
Taking the big leapfrog to advance T2D care
01 Dec 2021
During the Guardians for Health Summit 2021 supported by Boehringer Ingelheim, several distinguished speakers shared their insights into the importance of type 2 diabetes (T2D) guideline adherence and patient empowerment, as well as the impact of clinical inertia on the burden of cardiorenal metabolic diseases.
Product Highlight - Evenity
01 Dec 2021
Romosozumab 105 mg/1.17 mL soln for inj
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
Conference Reports
Evinacumab reduces LDL-C levels in homozygous FH
Elaine Soliven, 09 Dec 2021
Treatment with evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C) levels in adolescents and adults with homozygous familial hypercholesterolaemia (FH), according to a study presented at AHA 2021.
Increased serum iron may hint at HCC risk in NAFLD patients
Roshini Claire Anthony, 07 Dec 2021

Increased serum iron or transferrin saturation levels in individuals with non-alcoholic fatty liver disease (NAFLD) may point to an increased risk of hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting Digital Experience™.

Switching to TAF helps improve virologic response in HBV patients in real world
Pearl Toh, 06 Dec 2021
Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.
Interim findings boost therapeutic potential of lanifibranor for NASH
Audrey Abella, 06 Dec 2021
The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.
Empagliflozin beneficial and well tolerated in acute heart failure
Christina Lau, 06 Dec 2021

Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.

Canagliflozin improves HF symptoms, QoL regardless of diabetes status
Pearl Toh, 04 Dec 2021
The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.
Non-overweight NAFLD patients have poor liver transplant outcomes
Roshini Claire Anthony, 03 Dec 2021

Non-overweight patients with non-alcoholic fatty liver disease (NAFLD) have an elevated risk of all-cause mortality following liver transplant and are also more likely to be removed from the liver transplant waitlist compared with obese/overweight patients, according to a study presented at The Liver Meeting Digital Experience™.